Daniel E. Abbott, MD, FACS
Dr. Daniel E. Abbott is a surgical oncologist and Surgical Director of the University of Wisconsin School of Medicine and Public Health’s Liver and Pancreas Center. His clinical focus is on gastrointestinal malignancies, including malignant peritoneal mesothelioma as well as melanoma and sarcoma.[1]
He performs both traditional and minimally invasive laparoscopic resections for cancers of the liver, pancreas, and stomach. As the Director of Cytoreductive and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Surgery, Dr. Abbott is particularly interested in patients with malignant peritoneal mesothelioma and peritoneal spread of appendiceal, colorectal and ovarian cancers.[1]
Education and Career
Dr. Abbott earned his medical degree at the University of Washington School of Medicine in Seattle, Washington. He completed his internship and General Surgery Residency at the Northwestern University/Feinberg School of Medicine in Chicago, Illinois. Then he completed a research fellowship at Children’s Memorial Research Center/Northwestern University’s Division of Cancer Biology and Epigenomics. He also completed a Surgical Oncology fellowship in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas.[1]
Professional Memberships and Activities
Dr. Abbott is active in several national medical organizations including the Society of Surgical Oncology, the American Hepatopancreaticobiliary Association, the Association for Academic Surgery, and the Society of University Surgeons. He is certified by the American Board of Surgery and is a Fellow of the American College of Surgeons.[1]
Research
Dr. Abbott’s research is focused on cost-effectiveness, systems efficiency, and socioeconomic disparity in cancer care. He is particularly interested in identifying opportunities to maintain or enhance cancer care using technology in a patient-centered manner, thereby helping patients access expert cancer care in more personalized settings.
His most recent publications include:[1]
- The overlooked factor: The impact of disability on postoperative complications after emergency general surgery procedures surgery.
Sigler G, Abbott DE
Surgery 2024 Apr 12;
[PubMed ID: 38614910] - Preoperative CA 19-9 Predicts Disease Progression in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Analysis from the US HIPEC Collaborative.
Fackche NT, Schmocker RK, Nudotor R, Kubi B, Cloyd JM, Grotz TE, Fournier KF, Dineen SP, Veerapong J, Baumgartner JM, Clarke CN, Patel SH, Wilson GC, Lambert LA, Pokrzywa C, Abbott DE, Lee B, Staley CA, Zaidi MY, Johnston FM, Greer JB
Ann Surg Oncol 2024 May; 31(5): 3314-3324
[PubMed ID: 38310181] - ASO Visual Abstract: Association of Neighborhood Disadvantage with Short- and Long-Term Outcomes After Pancreatectomy for Pancreatic Ductal Adenocarcinoma.
Marcinak CT, Praska CE, Vidri RJ, Taylor AK, Krebsbach JK, Ahmed KS, LoConte NK, Varley PR, Afshar M, Weber SM, Abbott DE, Mathew J, Murtaza M, Burkard ME, Churpek MM, Zafar SN
Ann Surg Oncol 2024 Jan; 31(1): 552-553
[PubMed ID: 37805945] - Weekend Discharge Is Not Associated With Increased Readmission After Hyperthermic Intraperitoneal Chemotherapy.
Florissi I, Radomski SN, Shou B, Cloyd JM, Kim A, Grotz T, Fournier K, Baumgartner JM, Lambert L, Abbott DE, Schwartz P, Staley CA, Clarke C, Dineen S, Patel SH, Wilson GC, Raoof M, Johnston FM, Greer JB
J Surg Res 2024 Jan; 293: 403-412
[PubMed ID: 37806228] - Association of Neighborhood Disadvantage with Short- and Long-Term Outcomes After Pancreatectomy for Pancreatic Ductal Adenocarcinoma.
Marcinak CT, Praska CE, Vidri RJ, Taylor AK, Krebsbach JK, Ahmed KS, LoConte NK, Varley PR, Afshar M, Weber SM, Abbott DE, Mathew J, Murtaza M, Burkard ME, Churpek MM, Zafar SN
Ann Surg Oncol 2024 Jan; 31(1): 488-498
[PubMed ID: 37782415]
